Lord, Abbett & Co
SMMT icon

Lord, Abbett & Co’s Summit Therapeutics SMMT Stock Holding History

Lord, Abbett & Co’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-155,514
Closed -$3M – 578
2025
Q1 		$3M Buy
+155,514
New +$3.12M 0.01% 495

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Lord, Abbett & Co's SMMT Position: Q2 2025 in Review

Lord, Abbett & Co sold out of Summit Therapeutics (SMMT) in Q2 2025, closing a stake of 155,514 shares — an estimated $3M sold.

Lord, Abbett & Co first reported a position in SMMT in Q1 2025 and held it in 1 quarter. The position peaked at $3M in Q1 2025. 238 funds tracked by Wall St. Rank hold SMMT as of Q2 2025.

  • Lord, Abbett & Co reported no remaining Summit Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Lord, Abbett & Co sold 155,514 Summit Therapeutics shares in Q2 2025, an estimated $3M.
  • Lord, Abbett & Co first reported a position in Summit Therapeutics in Q1 2025 and held it in 1 quarter.
  • Lord, Abbett & Co's Summit Therapeutics position peaked at $3M in Q1 2025.
  • 238 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2025.

Based on Lord, Abbett & Co's 13F filing for Q2 2025, filed 14 Aug 2025.